论文信息 - Post‐marketing survey of donepezil hydrochloride in Japanese patients with Alzheimer's disease with behavioral and psychological symptoms of dementia (BPSD)

Post‐marketing survey of donepezil hydrochloride in Japanese patients with Alzheimer's disease with behavioral and psychological symptoms of dementia (BPSD)

Background: To investigate the efficacy and safety of donepezil hydrochloride (Aricept®; Eisai Co., Ltd, Tokyo, Japan), we conducted a post‐marketing survey in Japanese patients with Alzheimer's disease (AD) who also had behavioral and psychological symptoms of dementia (BPSD), such as hallucinations/delusions, wandering, and aggression, which cause the greatest burden on caregivers.

[1] Bruno Vellas,et al. Efficacy of Donepezil on Behavioral Symptoms in Patients With Moderate to Severe Alzheimer's Disease , 2002, International Psychogeriatrics.

[2] H. Feldman,et al. Functional, Cognitive and Behavioral Effects of Donepezil in Patients with Moderate Alzheimer's Disease , 2002, Current medical research and opinion.

[3] H. Feldman,et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease , 2001, Neurology.